Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Gilead Sciences Inc

Healthcare US GILD

128.99USD
1.42(1.11%)

Last update at 2026-06-03T20:26:00Z

Day Range

127.50129.86
LowHigh

52 Week Range

90.95156.40
LowHigh

Fundamentals

  • Previous Close 127.57
  • Market Cap165440.03M
  • Volume6211146
  • P/E Ratio19.66
  • Dividend Yield2.33%
  • EBITDA14577.00M
  • Revenue TTM29443.00M
  • Revenue Per Share TTM23.67
  • Gross Profit TTM 23213.00M
  • Diluted EPS TTM6.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 9796.00M 690.00M 6859.00M 5814.00M 8278.00M
Minority interest 0.00000M 0.00000M 47.00M 26.00M 24.00M
Net income 8510.00M 480.00M 5665.00M 4592.00M 6225.00M
Selling general administrative 5708.00M 2638.00M 6502.00M 5673.00M 5246.00M
Selling and marketing expenses - 3453.00M 826.00M - -
Gross profit 25523.00M 22503.00M 27116.00M 21624.00M 20704.00M
Reconciled depreciation 2760.00M 2767.00M 2533.00M 2103.00M 2050.00M
Ebit - 1667.00M 7605.00M 7330.00M 7406.00M
Ebitda 10820.00M 4434.00M 7605.00M 10393.00M 9456.00M
Depreciation and amortization - 2767.00M -1763.00000M 3063.00M 2050.00M
Non operating income net other - - - -581.00000M -639.00000M
Operating income 11817.00M 1662.00M 7605.00M 7330.00M 7406.00M
Other operating expenses 17626.00M 27092.00M 19511.00M 16307.00M 17210.00M
Interest expense 1024.00M 977.00M 944.00M 935.00M 1001.00M
Tax provision 1286.00M 211.00M 1408.00M 1248.00M 2077.00M
Interest income 349.00M 281.00M 376.00M - -
Net interest income -675.00000M -696.00000M -918.00000M -935.00000M -1001.00000M
Extraordinary items - - - - -
Non recurring - - - 3644.00M -
Other items - - - - -
Income tax expense 1286.00M 211.00M -1247.00000M 1248.00M 2077.00M
Total revenue 29443.00M 28754.00M 27116.00M 27281.00M 27305.00M
Total operating expenses 13706.00M 20841.00M 11808.00M 10650.00M 10609.00M
Cost of revenue 3920.00M 6251.00M 5804.00M 5657.00M 6601.00M
Total other income expense net -2021.00000M -972.00000M -746.00000M -1516.00000M 872.00M
Discontinued operations - - - - -
Net income from continuing ops 8510.00M 479.00M 5829.00M 4566.00M 6201.00M
Net income applicable to common shares - - - 4592.00M 6225.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 59023.00M 58995.00M 62125.00M 63171.00M 67952.00M
Intangible assets 16978.00M 19948.00M 26454.00M 28894.00M 33455.00M
Earning assets - - - - -
Other current assets 1143.00M 1475.00M 2374.00M 1774.00M 2141.00M
Total liab 36405.00M 39749.00M 39376.00M 41962.00M 46888.00M
Total stockholder equity 22618.00M 19330.00M 22749.00M 21209.00M 21064.00M
Deferred long term liab - - - 2673.00M 4356.00M
Other current liab 11813.00M 8526.00M 11280.00M 8059.00M 9389.00M
Common stock 22618.00M 1.00M 1.00M 1.00M 1.00M
Capital stock 1.00M 1.00M 1.00M 1.00M 1.00M
Retained earnings 13730.00M 11497.00M 16304.00M 15687.00M 16324.00M
Other liab - - - 7301.00M 35278.00M
Good will 8314.00M 8314.00M 8314.00M 8314.00M 8332.00M
Other assets - - - 1.00M 5988.00M
Cash 7564.00M 9991.00M 6085.00M 5412.00M 5338.00M
Cash and equivalents - - - - -
Total current liabilities 11813.00M 12004.00M 11280.00M 11237.00M 11610.00M
Current deferred revenue - - -2348.00000M - -
Net debt 17028.00M 16720.00M 18902.00M 19818.00M 21357.00M
Short term debt - 1815.00M 1798.00M 2273.00M 1516.00M
Short long term debt 2807.00M 1815.00M 1798.00M 2273.00M 1516.00M
Short long term debt total 24592.00M 26711.00M 24987.00M 25230.00M 26695.00M
Other stockholder equity 22618.00M 7700.00M -16332.00000M 5519.00M 4656.00M
Property plant equipment - - - 5475.00M 5121.00M
Total current assets 19886.00M 19173.00M 16454.00M 15227.00M 15056.00M
Long term investments 2974.00M 0.00000M 1163.00M 1245.00M 1309.00M
Net tangible assets - - - -15968.00000M -20723.00000M
Short term investments 3041.00M 1577.00M 1179.00M 973.00M 1182.00M
Net receivables 4913.00M 4420.00M 4660.00M 4777.00M 4493.00M
Long term debt 22129.00M 24896.00M 23189.00M 22957.00M 25179.00M
Inventory 4368.00M 1710.00M 3366.00M 2820.00M 2734.00M
Accounts payable 715.00M 833.00M 550.00M 905.00M 705.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - -84.00000M -31.00000M -5.00000M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 132.00M 28.00M 2.00M 83.00M
Additional paid in capital - - 6500.00M - -
Common stock total equity - - - 1.00M 1.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 15687.00M 16324.00M
Treasury stock - - 0.00000M - -
Accumulated amortization - - - - -
Non currrent assets other 8239.00M 6146.00M 5586.00M 4016.00M 5988.00M
Deferred long term asset charges - - - - -
Non current assets total 39137.00M 39822.00M 45671.00M 47944.00M 52896.00M
Capital lease obligations - - - - -
Long term debt total - - - 22957.00M 25179.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -3163.00000M -3449.00000M -1913.00000M -2466.00000M -3131.00000M
Change to liabilities - - - -1117.00000M 207.00M
Total cashflows from investing activities -4793.00000M -3449.00000M -2265.00000M -2466.00000M -3131.00000M
Net borrowings -1788.00000M 1494.00M -270.00000M -1500.00000M -4750.00000M
Total cash from financing activities -7745.00000M -3433.00000M -5125.00000M -6469.00000M -8877.00000M
Change to operating activities - - - -705.00000M 647.00M
Net income 8510.00M 480.00M 5665.00M 4566.00M 6201.00M
Change in cash -2427.00000M 3906.00M 673.00M 74.00M -659.00000M
Begin period cash flow 9991.00M 6085.00M 5412.00M 5338.00M 5997.00M
End period cash flow 7564.00M 9991.00M 6085.00M 5412.00M 5338.00M
Total cash from operating activities 10019.00M 10828.00M 8006.00M 9072.00M 11384.00M
Issuance of capital stock 408.00M 422.00M 382.00M 309.00M 169.00M
Depreciation 2760.00M 2767.00M 2693.00M 2103.00M 2050.00M
Other cashflows from investing activities 3.00M 58.00M - -1798.00000M -3131.00000M
Dividends paid 4003.00M 3918.00M 3809.00M -3709.00000M -3605.00000M
Change to inventory -1036.00000M -426.00000M -842.00000M -310.00000M 11.00M
Change to account receivables -367.00000M 139.00M 157.00M -406.00000M 313.00M
Sale purchase of stock -1922.00000M -1150.00000M -1000.00000M -1396.00000M -546.00000M
Other cashflows from financing activities -440.00000M -281.00000M -278.00000M -173.00000M -145.00000M
Change to netincome - - - 3509.00M 11384.00M
Capital expenditures 563.00M 523.00M 585.00M 728.00M 579.00M
Change receivables - - - -406.00000M 313.00M
Cash flows other operating - - - 727.00M 689.00M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 137.00M -624.00000M
Change in working capital -3948.00000M -880.00000M -2303.00000M -1763.00000M 489.00M
Stock based compensation 894.00M 835.00M 766.00M 637.00M 635.00M
Other non cash items 2537.00M 9470.00M 2147.00M 5081.00M 2125.00M
Free cash flow 9456.00M 10305.00M 7421.00M 8344.00M 10805.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GILD
Gilead Sciences Inc		 1.42 1.11% 128.99 19.66 15.50 5.62 7.43 6.25 13.55
LLY
Eli Lilly and Company		 14.63 1.37% 1078.78 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 0.35 0.16% 223.24 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 1.73 0.80% 217.13 86.32 14.33 5.89 50.46 7.04 24.44
AZN
AstraZeneca PLC		 -1.17 0.66% 176.28 30.69 19.23 5.30 6.45 5.72 17.23

Reports Covered

Stock Research & News

View All

Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences Inc

333 Lakeside Drive, Foster City, CA, United States, 94404

Key Executives

Name Title Year Born
Mr. Daniel P. O'Day Chairman & CEO 1964
Mr. Andrew D. Dickinson Exec. VP & CFO 1970
Ms. Johanna Mercier Chief Commercial Officer 1970
Dr. Merdad V. Parsey M.D., Ph.D. Chief Medical Officer 1963
Ms. Diane E. Wilfong Sr. VP, Corp. Controller & Chief Accounting Officer 1962
Ms. Jacquie Ross C.F.A. VP of Investor Relations NA
Ms. Deborah H. Telman Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. 1965
Ms. Jyoti K. Mehra Exec. VP of HR 1976
Dr. Michael Quigley Ph.D. Sr. VP of Research Biology NA
Dr. Linda Slanec Higgins Ph.D. Sr. VP & Head of External Innovation 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions